Investigator: Kathryn R Wagner MD PhD
Category: Research - Clinical
This is a proposal to study the histopathological features of muscle in a large biobank from FSHD patients and their first degree family members. By establishing a detailed morphometric signature of FSHD, we will be able to develop muscle pathology as an outcome measure in future clinical trials. Further, by correlating specific features such as degeneration and inflammation with DUX4 expression, we will be able to determine whether DUX4 has a primary or secondary effect on muscle pathology.
Related Material
Grant Information
Date awarded: Oct 25, 2016
End date: Oct 24, 2017
Amount awarded: $77,604
Kennedy Krieger Institute
Kathryn R Wagner MD PhD
Vice President and Global Head of Neuromuscular Disease
La Roche
Connect with us on social media